The Neurofibromatosis Therapeutic Acceleration Program (NTAP), a research enterprise based in the Johns Hopkins School of Medicine focused on therapeutics for NF1-associated peripheral nerve sheath tumors, launched a think tank to address core questions pertaining to the development of effective therapeutics for cNF in people with NF1. Here, NPHS1 is linked to neurofibromatosis.